Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antithrombin III

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Antithrombin III. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-004307-40 Sponsor Protocol Number: ATN-106 Start Date*: 2022-01-31
    Sponsor Name:Octapharma AG
    Full Title: A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing sur...
    Medical condition: Congenital antithrombin deficiency
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004850 10083881 Antithrombin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) AT (Ongoing) FR (Ongoing) IT (Ongoing) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001659-42 Sponsor Protocol Number: ANTITROMBINA Start Date*: 2020-04-18
    Sponsor Name:Fundación para la Investigación Biomédica de Córdoba
    Full Title: Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19
    Medical condition: Confirmed SARS-CoV-2 respiratory infection with poor prognostic factors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10051905 Coronavirus infection LLT
    20.1 10021881 - Infections and infestations 10061982 Severe acute respiratory syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003728-39 Sponsor Protocol Number: Euro SPK 003 Start Date*: 2010-12-07
    Sponsor Name:Centre Hospitalier Universitaire de Liège
    Full Title: A EUROPEAN MULTICENTER OPEN-LABEL RANDOMIZED TRIAL TO EVALUATE THE REDUCTION OF ISCHEMIA / REPERFUSION INJURY AFTER DE NOVO SIMULTANEOUS PANCREAS/KIDNEY TRANSPLANTATION IN TYPE 1-DIABETIC PATIENTS ...
    Medical condition: End-stage, C-peptide-negative, type 1-diabetic patients undergoing a first combined pancreas/kidney transplantation from a cadaver donor only will be enrolled in the study
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020377-16 Sponsor Protocol Number: ATIII Start Date*: 2009-11-20
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
    Full Title: EFFECTS OF THE ADMINISTRATION OF ANTITHROMBIN ON THE EMOCOAGULATIVE STATE AND ON THE INFLAMMATORY RESPONSE IN PATIENT WITH LOW PLASMATIC LEVELS OF ANTITHROMBIN AFTER CARDIAC INTERVENTIONS
    Medical condition: Patients candidates for cardiac surgery intervention in extracorporeal circulation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007541 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007313-68 Sponsor Protocol Number: IG0801 Start Date*: 2009-01-07
    Sponsor Name:GRIFOLS ITALIA
    Full Title: A Prospective Randomized Pilot study to evaluate the effect of preoperative antithrombin supplementation on postoperative levels of antithrombin in patients undergoing cardiac surgery with cardiopu...
    Medical condition: Subjects undergoing elective cardiac surgery with Cardio Pulmonar Bypass (CPB) having baseline levels of ATIII activity equal to or higher than 60% and below 100% under all circumstances.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057461 Cardiac procedure complication LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000099-12 Sponsor Protocol Number: APHP180617 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients
    Medical condition: Allograft vascular thrombosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10072226 Renal vascular thrombosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001642-26 Sponsor Protocol Number: LRD.2016.STREAM2 Start Date*: 2017-10-02
    Sponsor Name:Leuven Research & Development (LRD) at University of Leuven, Belgium
    Full Title: STREAM-2 (STrategic Reperfusion in elderly patients Early After Myocardial Infarction)
    Medical condition: ST-elevation myocardial infarction within 3 hours of onset of symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000011652 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-002328-34 Sponsor Protocol Number: KB056 Start Date*: Information not available in EudraCT
    Sponsor Name:KEDRION S.P.A
    Full Title: Efficacy and safety evaluation of Kedrion Fibrin Sealant as an adjuvant for the control of hemostasis in pediatric patients undergoing abdominal or orthopedic surgery. Multicenter, randomized, cont...
    Medical condition: Paediatric patients undergoing abdominal or orthopedic surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10067439 Haemostasis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003359-12 Sponsor Protocol Number: CCH2012-02 Start Date*: 2015-02-18
    Sponsor Name:VU University Medical Center
    Full Title: The effect of a high and low protamine-to-heparin dosing on perioperative hemostasis: a randomized clinical trial.
    Medical condition: Patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10006894 CABG LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001219-44 Sponsor Protocol Number: 1123.28 Start Date*: 2008-01-30
    Sponsor Name:Boehringer Ingelheim France
    Full Title: STREAM - STrategic Reperfusion Early After Myocardial Infarction Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antipla...
    Medical condition: ST-elevation myocardial infaction within 3 hours of onset of symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) GB (Completed) IT (Completed) ES (Completed) BE (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002873-35 Sponsor Protocol Number: LEO 90010-I21 Start Date*: 2007-04-24
    Sponsor Name:LEO Pharmaceutical Products Ltd A/S (LEO Pharma A/S)
    Full Title: Exploratory efficacy and safety, pharmacokinetics and dose-finding study of ATryn® (antithrombin alfa) in patients with disseminated intravascular coagulation associated with severe sepsis
    Medical condition: Disseminated intravascular coagulation associated with severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013442 Disseminated intravascular coagulation LLT
    9.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003866-96 Sponsor Protocol Number: BEMI-2015 Start Date*: 2016-04-29
    Sponsor Name:ANGELA PUENTE
    Full Title: Randomized controlled trial on the safety and efficacy of low molecular weight heparins in the prevention of thrombotic events in hospitalized cirrhotic patients
    Medical condition: Prevention of thrombosis in cirrhotic patients
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005788-34 Sponsor Protocol Number: NL79578.100.21 Start Date*: 2022-03-31
    Sponsor Name:St. Antonius Hospital
    Full Title: Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect
    Medical condition: Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017095-24 Sponsor Protocol Number: AOP13007 Start Date*: 2010-02-17
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A phase III, randomized, multicenter, subject- and sponsor-blinded, placebo controlled study to compare the efficacy and safety of “Anagrelide retard” versus placebo in “at risk” subjects with Esse...
    Medical condition: male and female "at risk" subjects with Essential Thrombocythaemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) SI (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-020113-85 Sponsor Protocol Number: CSLCT-BIO-l0-67 Start Date*: 2011-09-20
    Sponsor Name:CSL Behring GmbH
    Full Title: A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to evaluate Plasma-Derived Antihaemophilic Factor/von Willebrand Factor Concentrate (Biostate®) for Immune To...
    Medical condition: Male paediatric subjects with Haemophilia A who develped high titre antibodies to human coagulation Factor VIII
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10018941 Haemophilia NOS LLT
    Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) FR (Completed) AT (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001779-31 Sponsor Protocol Number: FONDAPARINUX Start Date*: 2008-05-09
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: Markers of hypercoagulability and risk of death and rehospitalization in heart failure patients: a pilot study on the effects of Fondaparinux
    Medical condition: heart failure patients (III-IV NYHA)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001239-30 Sponsor Protocol Number: CIR976101 Start Date*: 2012-05-22
    Sponsor Name:Foundation for Liver Research
    Full Title: THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY.
    Medical condition: Liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000565-40 Sponsor Protocol Number: GLM101-002 Start Date*: 2022-11-04
    Sponsor Name:Glycomine, Inc
    Full Title: A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participa...
    Medical condition: PMM2-CDG
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10027426 Metabolic disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000572-15 Sponsor Protocol Number: GRASPANC-2018-01 Start Date*: 2018-11-06
    Sponsor Name:ERYTECH Pharma
    Full Title: A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma
    Medical condition: Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing) SE (Completed) ES (Completed) AT (Completed) DE (Completed) NL (Completed) DK (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002816-22 Sponsor Protocol Number: CTL-002-002 Start Date*: 2023-03-09
    Sponsor Name:Catalym GmbH
    Full Title: A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
    Medical condition: Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA